Cost‐effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non‐small cell lung cancer

BACKGROUND: The monoclonal antibody durvalumab, an immune‐checkpoint inhibitor (ICI) antiprogrammed death ligand 1 (PD‐L1), is available for unresectable stage III NSCLC patients as consolidation therapy following induction chemoradiotherapy, with very promising overall survival (OS) and progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Buja, Alessandra, Pasello, Giulia, Schiavon, Marco, De Luca, Giuseppe, Rivera, Michele, Cozzolino, Claudia, De Polo, Anna, Scioni, Manuela, Bortolami, Alberto, Baldo, Vincenzo, Conte, PierFranco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527163/
https://www.ncbi.nlm.nih.gov/pubmed/35971638
http://dx.doi.org/10.1111/1759-7714.14531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527163/
https://www.ncbi.nlm.nih.gov/pubmed/35971638
http://dx.doi.org/10.1111/1759-7714.14531

Ejemplares similares